Last reviewed · How we verify

NCT00609596

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

Completed Phase 1 Last updated 4 August 2017
What this trial tests

Phase 1 trial testing GI198745 in Prostatic Hyperplasia in 24 participants. Completed in 23 April 2008.

Timeline
26 February 2008
Primary endpoint
23 April 2008
23 April 2008

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date26 February 2008
Primary completion23 April 2008
Estimated completion23 April 2008
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 45, male only, with Prostatic Hyperplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dutasteride and tamsulosin are to treat benign prostatic hyperplasia. Studies show that when given together, there is more improvement in symptoms than either drug alone. In this study, we are looking to see if 2 different formulations of tamsulosin in our combination capsules are the same after 7 days of dosing as the US commercial tamsulosin and dutasteride.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prostatic Hyperplasia

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00609596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing